The long-term objectives of this proposal are to define the pharmacokinetics of GHB and its precursors, including their nonlinear (i.e., dose- and concentration-dependent) characteristics, and to examine how these properties may affect their renal clearance, brain distribution and effects, and gene regulation during tolerance and withdrawal. The goal of this work, therefore, is to delineate the relationships between GHB/precursor dose and blood/urine concentrations, the clearance rate of these compounds at particular concentrations (toxicokinetics), and the relationships between blood/brain concentrations and the relevant toxic effects (toxicodynamics). We submit that basic knowledge about these aspects of GHB pharmacology, obtained through animal models, is critical for the rational management of GHB toxicity and abuse.
Three specific aims are proposed.
The first aim will characterize the toxicokinetics, renal clearance and renal transport of GHB/precursors. Although the urinary excretion of GHB has been reported to be minor (less than 10 percent) in animals and in humans, GHB overdoses have been associated with extremely high urinary concentrations of GHB and its precursors. We hypothesize that GHB renal clearance may be governed in part by saturable re-absorption, possibly mediated by monocarboxylate anion transporters.
Aim 1 will therefore examine the pharmacokinetics and mechanisms of GHB/precursor clearance, and will test the hypothesis that GHB renal clearance may be affected by urinary pH and presence of transport inhibitors. The effect of gender on GHB pharmacokinetics will also be examined.
Specific aim number 2 will examine the toxicokinetics and brain toxicodynamics of GHB/precursors under single and chronic dosing conditions. We shall test the hypothesis that the dissimilar pharmacokinetic and physicochemical properties between GHB and its precursors will result in significantly different brain toxicokinetics and subsequent differences in neurochemical and membrane biophysical effects. The presence of brain transporters that may mediate GHB transport across the blood-brain barrier will also be examined.
Specific aim number 3 will examine how various factors may affect the regulation of gene expression in the brain that are induced by GHB and its precursors, particularly during tolerance development and withdrawal. Multiple biochemical pathways are associated with GHB action, and we therefore hypothesize that GHB/precursor exposure causes a myriad of changes in gene regulation, which will be monitored by the contemporary technique of micro gene-array determination. A pharmacogenetic mapping of the pharmacological effects of GHB will be obtained. The effects of tolerance development, withdrawal, gender, receptor blockade on these effects will be examined.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1-RXL-E (08))
Program Officer
Rapaka, Rao
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
State University of New York at Buffalo
Schools of Pharmacy
United States
Zip Code
Vijay, Nisha; Morse, Bridget L; Morris, Marilyn E (2015) A Novel Monocarboxylate Transporter Inhibitor as a Potential Treatment Strategy for ?-Hydroxybutyric Acid Overdose. Pharm Res 32:1894-906
Fung, Ho-Leung; Tsou, Pei-Suen; Bulitta, Jurgen B et al. (2008) Pharmacokinetics of 1,4-butanediol in rats: bioactivation to gamma-hydroxybutyric acid, interaction with ethanol, and oral bioavailability. AAPS J 10:56-69
Morris, Marilyn E; Felmlee, Melanie A (2008) Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J 10:311-21
Wang, Xiaodong; Wang, Qi; Morris, Marilyn E (2008) Pharmacokinetic interaction between the flavonoid luteolin and gamma-hydroxybutyrate in rats: potential involvement of monocarboxylate transporters. AAPS J 10:47-55
Wang, Qi; Lu, Ye; Morris, Marilyn E (2007) Monocarboxylate transporter (MCT) mediates the transport of gamma-hydroxybutyrate in human kidney HK-2 cells. Pharm Res 24:1067-78
Wang, Qi; Morris, Marilyn E (2007) The role of monocarboxylate transporter 2 and 4 in the transport of gamma-hydroxybutyric acid in mammalian cells. Drug Metab Dispos 35:1393-9
Wang, Qi; Morris, Marilyn E (2007) Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo. Drug Metab Dispos 35:201-8
Page, Nathaniel A; Paganelli, Meaghan; Boje, Kathleen M K et al. (2007) An interactive lesson in acid/base and pro-drug chemistry using sodium gamma-hydroxybutyrate and commercial test coasters. Am J Pharm Educ 71:54
Bhattacharya, Indranil; Boje, Kathleen M K (2007) Feasibility of D-glucuronate to enhance gamma-hydroxybutyric acid metabolism during gamma-hydroxybutyric acid toxicity: pharmacokinetic and pharmacodynamic studies. Biopharm Drug Dispos 28:1-11
Raybon, Joseph J; Boje, Kathleen M K (2007) Pharmacokinetics and pharmacodynamics of gamma-hydroxybutyric acid during tolerance in rats: effects on extracellular dopamine. J Pharmacol Exp Ther 320:1252-60

Showing the most recent 10 out of 17 publications